NASDAQ:NMRA • US6409791000
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEUMORA THERAPEUTICS INC (NMRA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-17 | William Blair | Upgrade | Market Perform -> Outperform |
| 2026-01-12 | Leerink Partners | Initiate | Outperform |
| 2025-12-01 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2025-11-17 | Stifel | Maintains | Hold -> Hold |
| 2025-10-28 | Needham | Maintains | Buy -> Buy |
| 2025-10-27 | Guggenheim | Upgrade | Neutral -> Buy |
| 2025-09-16 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2025-07-16 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-05-13 | Needham | Reiterate | Buy -> Buy |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-04-02 | B of A Securities | Downgrade | Buy -> Underperform |
| 2025-03-10 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-03-07 | Stifel | Downgrade | Buy -> Hold |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-04 | Needham | Reiterate | Buy -> Buy |
| 2025-03-04 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-03-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-06 | B of A Securities | Maintains | Buy -> Buy |
| 2025-01-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-02 | Needham | Reiterate | Buy -> Buy |
| 2024-12-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-22 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-13 | Needham | Reiterate | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 1,042.71% | N/A 155.64% | N/A 106.31% | N/A 68.78% | N/A 72.45% | N/A 59.49% | |||||||
| EBITDA YoY % growth | -20K | -25.39M -126,850.00% | -79.78M -214.22% | -122.28M -53.27% | -187.526M -53.36% | -262.833M -40.16% | N/A 8.03% | N/A 43.88% | N/A -3.76% | N/A -58.26% | N/A -5.13% | N/A 40.51% | N/A 76.13% | N/A 258.59% | N/A 351.64% | |
| EBIT YoY % growth | -20K | -25.5M -127,400.00% | -80.32M -214.98% | -122.87M -52.98% | -188.194M -53.17% | -263.464M -40.00% | N/A 8.34% | N/A 22.68% | N/A -21.82% | N/A 3.23% | N/A 42.61% | N/A 132.58% | N/A 323.79% | N/A 244.95% | N/A 113.40% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | -1.53 14.22% | N/A 5.00% | N/A 27.46% | N/A 2.30% | N/A 12.28% | N/A 59.37% | N/A 212.03% | N/A 247.95% | N/A 93.59% | N/A 75.70% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.33 10.25% | -0.32 23.09% | -0.29 13.45% | -0.26 20.31% | -0.25 25.51% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -55.08M 11.58% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -55.104M 12.42% | -53.805M 24.15% | -49.368M 8.65% | -41.004M 22.19% | -37.128M 32.62% |
All data in USD
15 analysts have analysed NMRA and the average price target is 9.33 USD. This implies a price increase of 259.89% is expected in the next year compared to the current price of 2.5913.
NEUMORA THERAPEUTICS INC (NMRA) will report earnings on 2026-03-30, before the market open.
The consensus EPS estimate for the next earnings of NEUMORA THERAPEUTICS INC (NMRA) is -0.33 USD and the consensus revenue estimate is 0 USD.